Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
BTK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
BTK Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Bruton Tyrosine Kinase (BTK) Inhibitors inhibit the BTK enzymes, which is a crucial element in the B cell signaling pathway that is used by particular B-cell receptor signaling pathways. B cell is a type of lymphocyte that has many immunoglobulins present on its surface. These immunoglobulins interact with other immunoglobulins and or antigens in the circulation. When the immunoglobulin attaches itself to the surface of the antigen and identifies it as a potential threat, it and T cells multiply into hundreds of cells. Activation of B cells induces BTK enzyme that communicates with other immune system cells and its proliferation. Therefore, inhibiting BTK can have several effects such as reducing cell migration, proliferation, and survival, as well as disrupting integrin-mediated adhesion to fibronectin, inhibiting DNA synthesis, diminishing cellular response to tissue homing chemokines (CXCL12, CXCL13, CCL19), and inducing apoptosis. Therefore, these reduce the proliferation of malignant B cells. These inhibitors are used for diseases associated with lymphocytes and are giving promising results with many candidates in clinical trials. Extensive research is being conducted globally to discover new and novel molecules to be used as BTK Inhibitors, like Calquence which is used for the treatment of Chronic Lymphocytic Leukemia (CLL). The development and launch of new products will thus increase the market’s revenue in the forecasted years. According to the American Cancer Society 2023 report, about 59,610 new leukemia cancer cases are to be reported in the USA, from which 18,740 new cases will be of CLL estimated to be nearly 1/4th of leukemia cases. There has been a rise in the prevalence of leukemia for many years marking an opportunity for the market players globally.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. 47 companies have various products in their pipelines, with 46 products in different stages of clinical trials. 2 products in Phase 4, 13 in Phase 3, 20 in Phase 2, and 13 in Phase 1 of the clinical trials.
Key Developments of BTK Inhibitors
Approved Molecules Of BTK Inhibitors
Drugs In The Pipeline Of BTK Inhibitors
Clinical Activity and Developments of BTK Inhibitors
As of July 2023, 47 companies have approximately 46 products for 66 diseases. For these diseases, 527 trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Imbruvica (ibrutinib) |
393 |
|
Calquence (acalabrutinib) |
146 |
|
Brukinsa (zanubrutinib) |
99 |
|
Yinuokai (orelabrutinib) |
48 |
|
remibrutinib (LOU064) |
23 |
Drugs like Imbruvica (ibrutinib) and Calquence (acalabrutinib) have been approved by the FDA and other regulatory agencies to treat various diseases. Imbruvica and Calquence are anti-cancer medications used for multiple indications in adults like Mantle Cell Lymphoma (MLL) with at least one other prior treatment for it and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Imbruvica is also indicated for treating Waldenström’s macroglobulinemia (WM), Chronic graft vs host disease, and Marginal Zone Lymphoma (MZL) in adults. With the increase in the prevalence rates of the disorders indicated for the drugs, the prescription rate is bound to increase, increasing the sales of these drugs.
Imbruvica generated net revenue of $4,568 million globally in the financial year 2022, with $3,426 million from the USA and $1,142 million from the international market, with a 15.5% decrease in global sales in comparison with 2021. The net revenue of Imbruvica in the 4th quarter ended December 2022 was $1,115 million, with $841 million from the US market and $274 million from the international market, with a 19.5% decrease in global sales in comparison with 2021. Calquence generated net revenue of $2,057 million in the financial year with an increase of 66%, while the 4th quarter of 2022 had net sales of $558 million with an increase of 49%. The rise in the sales of Calquence is primarily due to its approval globally for various indications in recent years, taking over the sales of Imbruvica. There is a big market for existing and new players to generate revenue from.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Imbruvica (ibrutinib) and Calquence (acalabrutinib) are approved by various regulatory agencies.
The two approved drugs are used in adults for indications like Mantle Cell Lymphoma (MLL) with at least one other prior treatment for it and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Imbruvica is also indicated for treating Waldenström’s macroglobulinemia (WM), Chronic graft vs host disease, and Marginal Zone Lymphoma (MZL) in adults.
AbbVie, J&J, AstraZeneca, Novartis, and Eli Lilly are some of the major market players for BTK Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of cancers among the adults like Mantle Cell Lymphoma (MLL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and others are the key opportunities for BTK Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.